Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- Wall St rises as chip stocks' gains offset Middle East jitters
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil eases as investors assess US-Iran peace prospects
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
- S&P 500 ends down after Trump says Iran deal is 'over'
Kala Pharmaceuticals (KALA) Misses Q4 EPS by 3c
February 12, 2020 7:13 AM ESTKala Pharmaceuticals (NASDAQ: KALA) reported Q4 EPS of ($0.63), $0.03 worse than the analyst estimate of ($0.60). Revenue for the quarter came in at $1.2 million versus the consensus estimate of $2.95 million.
For earnings history and earnings-related data on Kala Pharmaceuticals (KALA) click here.
... More